Excellent writeup — exactly what I was looking for!
For anyone managing type 2 diabetes alongside obesity, the selection of a GLP-1 receptor agonist over other antidiabetic agents often makes compelling clinical sense. Beyond HbA1c reduction, the weight loss, cardiovascular protection, and potential renal benefits offer a more comprehensive metabolic impact than older drug classes. Liraglutide, dulaglutide, exenatide, and the newer longer-acting once-weekly formulations each have distinct pharmacokinetic profiles that can be matched to individual patient needs. The incretin effect, so central to how these drugs work, represents one of the more elegant examples of pharmacology aligning closely with human physiology.
Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro, has pushed the boundaries even further. Clinical trial data shows…
Excellent writeup — exactly what I was looking for!
For anyone managing type 2 diabetes alongside obesity, the selection of a GLP-1 receptor agonist over other antidiabetic agents often makes compelling clinical sense. Beyond HbA1c reduction, the weight loss, cardiovascular protection, and potential renal benefits offer a more comprehensive metabolic impact than older drug classes. Liraglutide, dulaglutide, exenatide, and the newer longer-acting once-weekly formulations each have distinct pharmacokinetic profiles that can be matched to individual patient needs. The incretin effect, so central to how these drugs work, represents one of the more elegant examples of pharmacology aligning closely with human physiology.
Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro, has pushed the boundaries even further. Clinical trial data shows…